$MBRX
Moleculin Biotech, Inc. Stock $mbrx

$mbrx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000143774924016031 Filed on May 10, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.064M	$2.393M	$2.252M
YoY Change	-17.17%	-9.25%	-20.65%
% of Gross Profit
Research & Development	$4.090M	$4.252M	$6.632M
YoY Change	5.2%	-25.23%	58.74%
% of Gross Profit
Depreciation & Amortization	$31.00K	$32.00K	$37.00K
YoY Change	0.0%	6.67%	15.63%
% of Gross Profit
Operating Expenses	$6.185M	$6.677M	$8.919M
YoY Change	-3.53%	-20.07%	26.55%
Operating Profit	-$6.185M	-$6.677M
YoY Change	-3.53%	-20.07%
Interest Expense	$159.0K	$241.0K	-$858.0K
YoY Change	-59.23%	-38.52%	-409.75%
% of Operating Profit
Other Income/Expense, Net	$11.00K	$11.00K	$18.00K
YoY Change	22.22%	37.5%	1700.0%
Pretax Income	-$4.319M	-$4.970M	-$10.27M
YoY Change	-27.73%	-37.21%	51.68%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.319M	-$4.970M	-$10.27M
YoY Change	-27.73%	-37.09%	51.68%
Net Earnings / Revenue
Basic Earnings Per Share	-$1.70	-$2.02
Diluted Earnings Per Share	-$1.70	-$2.02	-$5.09
COMMON SHARES
Basic Shares Outstanding	2.312M	2.228M	29.81M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.85M	$16.82M	$23.55M
YoY Change	-66.29%	-54.85%	-45.42%
Cash & Equivalents	$10.85M	$16.82M	$23.55M
Short-Term Investments
Other Short-Term Assets	$1.605M	$2.133M	$1.204M
YoY Change	-49.97%	5.39%	-14.18%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$13.73M	$18.96M	$26.27M
YoY Change	-61.19%	-51.75%	-42.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$221.0K	$240.0K	$272.0K
YoY Change	-3.49%	-1.64%	-1.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$11.84M	$11.89M	$11.94M
YoY Change	0.93%	0.98%	1.0%
TOTAL ASSETS
Total Short-Term Assets	$13.73M	$18.96M	$26.27M
Total Long-Term Assets	$11.84M	$11.89M	$11.94M
Total Assets	$25.58M	$30.85M	$38.22M
YoY Change	-45.72%	-39.59%	-33.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.833M	$2.104M	$2.498M
YoY Change	-31.5%	8.51%	19.24%
Accrued Expenses	$2.913M	$3.304M	$4.317M
YoY Change	20.47%	6.82%	58.48%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.746M	$5.408M	$6.815M
YoY Change	-12.33%	7.47%	41.42%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.124M	$3.850M	$5.329M
YoY Change	624.91%	1012.72%	1193.45%
Total Long-Term Liabilities	$2.124M	$3.850M	$5.329M
YoY Change	624.91%	1012.72%	1193.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.746M	$5.408M	$6.815M
Total Long-Term Liabilities	$2.124M	$3.850M	$5.329M
Total Liabilities	$7.870M	$9.258M	$12.14M
YoY Change	14.94%	72.15%	132.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$140.9M	-$136.6M	-$131.6M
YoY Change	21.78%	24.41%	29.27%
Common Stock	$158.6M	$158.2M	$157.7M
YoY Change	1.68%	1.77%	2.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.71M	$21.59M	$26.07M
YoY Change
Total Liabilities & Shareholders Equity	$25.58M	$30.85M	$38.22M
YoY Change	-45.72%	-39.59%	-33.45%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$4.319M	-$4.970M	-$10.27M
YoY Change	-27.73%	-37.09%	51.68%
Depreciation, Depletion And Amortization	$31.00K	$32.00K	$37.00K
YoY Change	0.0%	6.67%	15.63%
Cash From Operating Activities	-$5.949M	-$6.717M	-$5.411M
YoY Change	16.06%	11.95%	-25.43%
INVESTING ACTIVITIES
Capital Expenditures	$13.00K		$84.00K
YoY Change	-13.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$13.00K		-$84.00K
YoY Change	-13.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-25.00K	$0.00	4.461M
YoY Change	-151.02%	-100.0%
NET CHANGE
Cash From Operating Activities	-5.949M	-$6.717M	-5.411M
Cash From Investing Activities	-13.00K		-84.00K
Cash From Financing Activities	-25.00K	$0.00	4.461M
Net Change In Cash	-5.987M	-$6.726M	-1.034M
YoY Change	17.58%	14.39%	-85.75%
FREE CASH FLOW
Cash From Operating Activities	-$5.949M	-$6.717M	-$5.411M
Capital Expenditures	$13.00K		$84.00K
Free Cash Flow	-$5.962M		-$5.495M
YoY Change	15.97%		-24.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2311536
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2311536
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2227516
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2227516
CY2024Q1	mbrx	Number Of Core Drug Technologies NumberOfCoreDrugTechnologies	3	pure
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2024Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	12000	usd
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-37758
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4671997
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5300 Memorial Drive, Suite 950
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Houston
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77007
CY2024Q1	dei	City Area Code CityAreaCode	713
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	300-5160
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2024Q1	dei	Trading Symbol TradingSymbol	MBRX
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2311536
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16824000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23550000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2133000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2723000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	18957000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	26273000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	240000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	272000	usd
CY2024Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	11148000	usd
CY2023Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	11148000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	500000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	524000	usd
CY2024Q1	us-gaap	Assets Assets	30845000	usd
CY2023Q4	us-gaap	Assets Assets	38217000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2104000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2498000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3304000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4317000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5408000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6815000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	450000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	474000	usd
CY2024Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3400000	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4855000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	9258000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	12144000	usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	33000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	158177000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	157653000	usd
CY2024Q1	us-gaap	Aoci Before Tax Attributable To Parent AociBeforeTaxAttributableToParent	-18000	usd
CY2023Q4	us-gaap	Aoci Before Tax Attributable To Parent AociBeforeTaxAttributableToParent	-9000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-136574000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-131604000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	21587000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	26073000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30845000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38217000	usd
CY2024Q1	us-gaap	Revenues Revenues	0	usd
CY2023Q1	us-gaap	Revenues Revenues	0	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4252000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5687000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2393000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2637000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	30000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	6677000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	8354000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6677000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8354000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1455000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-39000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8000	usd
CY2024Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	241000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	392000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4970000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7915000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.02
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.13
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2466174
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1916665
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4970000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7915000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-4000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4979000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7919000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4970000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7915000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	30000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	493000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	499000	usd
CY2024Q1	mbrx	Common Stock Issued For Licence Rights Under License Agreement CommonStockIssuedForLicenceRightsUnderLicenseAgreement	0	usd
CY2023Q1	mbrx	Common Stock Issued For Licence Rights Under License Agreement CommonStockIssuedForLicenceRightsUnderLicenseAgreement	772000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1455000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-39000	usd
CY2024Q1	mbrx	Operating Lease Noncash Expense Net OperatingLeaseNoncashExpenseNet	108000	usd
CY2023Q1	mbrx	Operating Lease Noncash Expense Net OperatingLeaseNoncashExpenseNet	110000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-590000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-427000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-394000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-156000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1121000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	255000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6717000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6017000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	141000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	141000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-9000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-4000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6726000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5880000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23550000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43145000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16824000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37265000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	26073000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37000	usd
CY2024Q1	mbrx	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	0	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	456000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4970000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	21587000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	52191000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	141000	usd
CY2023Q1	mbrx	Stock Issued During Period Value License Rights StockIssuedDuringPeriodValueLicenseRights	772000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	499000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7915000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-4000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	45684000	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">1.</em> Nature of Business </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The terms “MBI” or “the Company”, “we”, “our” and “us” are used herein to refer to Moleculin Biotech, Inc. MBI is a clinical-stage pharmaceutical company, organized as a Delaware corporation in <em style="font: inherit;"> July 2015, </em>with clinical programs for hard-to-treat cancers and viruses. The Company has <span style="-sec-ix-hidden:c112562462">three</span> core technologies, each of which have had <em style="font: inherit;">one</em> or more drugs successfully complete a Phase <em style="font: inherit;">1</em> clinical trial, based substantially on discoveries made at and licensed from MD Anderson Cancer Center (MD Anderson) in Houston, Texas. The Company has <em style="font: inherit;">two</em> wholly owned subsidiaries, Moleculin Australia Pty. Ltd., which was set up to perform certain preclinical development and Moleculin Amsterdam B.V., which acts as its legal representative for clinical trials in Europe. The Company utilizes its own internal resources and funds to conduct some of these trials and also has trials being conducted via physician-sponsored trials. The physician-sponsored trials utilize primarily external funds, such as grant funds, which are <em style="font: inherit;">not</em> presented in these financial statements. The Company does <em style="font: inherit;">not</em> have manufacturing facilities and all manufacturing activities are contracted out to <em style="font: inherit;">third</em> parties. Additionally, the Company does <em style="font: inherit;">not</em> have a sales organization. The Company’s overall strategy is to seek potential out-licensing or outsourcing opportunities with development/commercialization strategic partners who are better suited for the marketing, sales and distribution of its drugs, if approved.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In <em style="font: inherit;">2019,</em> the Company sublicensed its technologies to Animal Life Sciences, Inc. (ALI), to enable research and commercialization for non-human use and share development data. As part of this agreement, ALI issued to the Company a 10% equity interest in ALI. </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> May 5, 2023, </em>the Company received a letter from the Nasdaq Capital Market (Nasdaq) notifying the Company that for the prior <em style="font: inherit;">30</em> consecutive business days the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on Nasdaq pursuant to Nasdaq Listing Rule <em style="font: inherit;">5550</em>(a)(<em style="font: inherit;">2</em>) (Bid Price Rule). The deficiency letter did <em style="font: inherit;">not</em> result in the immediate delisting of the Company's common stock from the Nasdaq. In accordance with Nasdaq Listing Rule <em style="font: inherit;">5810</em>(c)(<em style="font: inherit;">3</em>)(A), the Company was provided an initial period of <em style="font: inherit;">180</em> calendar days, until <em style="font: inherit;"> November 1, 2023, </em>to regain compliance with the Bid Price Rule. On <em style="font: inherit;"> November 2, </em><em style="font: inherit;">2023,</em> the Company received a 180-calendar day extension, until <em style="font: inherit;"> April 29, 2024, </em>from the Nasdaq to regain compliance with Bid Price Rule. On <em style="font: inherit;"> March 5, 2024, </em>the Board of Directors approved a reverse <em style="font: inherit;">1</em>-for-15 reverse stock split effective <em style="font: inherit;">11:59</em> P.M. (Eastern time) on <em style="font: inherit;"> March 21, 2024, </em>with trading to commence on a split-adjusted basis on <em style="font: inherit;"> March 22, 2024. </em>On <em style="font: inherit;"> April 8, 2024, </em>the Company received a letter from Nasdaq notifying the Company that it had regained compliance with Bid Price Rule <em style="font: inherit;">5550</em>(a)(<em style="font: inherit;">2</em>) as a result of the closing bid price of the Company's common stock being at $1.00 per share or greater for the <em style="font: inherit;">10</em> consecutive business days from <em style="font: inherit;"> March 22, 2024 </em>through <em style="font: inherit;"> April 5, 2024. </em>Accordingly, the Company is in compliance with the Bid Price Rule and Nasdaq considers the matter closed.</p>
CY2023Q2	mbrx	Nasdaq Compliance Minimum Closing Bid Price Per Share NASDAQComplianceMinimumClosingBidPricePerShare	1
	mbrx	Nasdaq Compliance Extension Period NASDAQComplianceExtensionPeriod	P180D
CY2023Q2	mbrx	Nasdaq Compliance Minimum Closing Bid Price Per Share NASDAQComplianceMinimumClosingBidPricePerShare	1
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><b>Use of Estimates -</b> The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors <em style="font: inherit;"> may </em>affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often <em style="font: inherit;"> may </em>yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process <em style="font: inherit;"> may </em>result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes. </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt; "></p>
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-136600000	usd
CY2024Q1	us-gaap	Cash Cash	16800000	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1700000
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	400000
CY2024Q1	mbrx	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	1565000	usd
CY2023Q4	mbrx	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	2845000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1092000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	765000	usd
CY2024Q1	mbrx	Accrued Legal Regulatory Professional And Other Current AccruedLegalRegulatoryProfessionalAndOtherCurrent	477000	usd
CY2023Q4	mbrx	Accrued Legal Regulatory Professional And Other Current AccruedLegalRegulatoryProfessionalAndOtherCurrent	547000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	109000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	100000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3304000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4317000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	6834
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	493000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	499000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	38000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	33000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	2000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	7000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	40000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	40000	usd
CY2023Q3	mbrx	Operating Lease Monthly Rent Payment OperatingLeaseMonthlyRentPayment	4700	usd
CY2023Q3	mbrx	Operating Lease Rent Expense Annual Increase In Rent Percent OperatingLeaseRentExpenseAnnualIncreaseInRentPercent	0.02	pure
CY2024Q1	us-gaap	Sublease Income SubleaseIncome	12000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	29000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	38000	usd
CY2024Q1	mbrx	License Agreements Expense LicenseAgreementsExpense	156000	usd
CY2023Q1	mbrx	License Agreements Expense LicenseAgreementsExpense	155000	usd

Files In Submission

Name	View Source	Status
0001437749-24-016031-index-headers.html	Edgar Link	pending
0001437749-24-016031-index.html	Edgar Link	pending
0001437749-24-016031.txt	Edgar Link	pending
0001437749-24-016031-xbrl.zip	Edgar Link	pending
ex_635408.htm	Edgar Link	pending
ex_635409.htm	Edgar Link	pending
ex_635410.htm	Edgar Link	pending
ex_635411.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
mbrx-20240331.xsd	Edgar Link	pending
mbrx20240331_10q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
moleculinnewlogoresized.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
mbrx-20240331_cal.xml	Edgar Link	unprocessable
mbrx-20240331_def.xml	Edgar Link	unprocessable
mbrx-20240331_pre.xml	Edgar Link	unprocessable
mbrx20240331_10q_htm.xml	Edgar Link	completed
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mbrx-20240331_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MBRX
Moleculin Biotech, Inc. Stock $mbrx

2024 Q2 Form 10-Q Financial Statement

#000143774924016031 Filed on May 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBRX Moleculin Biotech, Inc. Stock $mbrx

2024 Q2 Form 10-Q Financial Statement

#000143774924016031 Filed on May 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBRX
Moleculin Biotech, Inc. Stock $mbrx